Tylš F., Páleníček T., Fujáková M., Kadeřábek L., Nováková P
Transcription
Tylš F., Páleníček T., Fujáková M., Kadeřábek L., Nováková P
THE COMPARISON OF SENSORIMOTOR GATING AND QUANTITATIVE EEG IN RATS IN SEROTONERGIC MODELS OF PSYCHOSIS Tylš F., Páleníček T., Fujáková M., Kadeřábek L., Nováková P., Kubešová A., Krajča V., Horáček J. Psychiatric centre Prague, Czech Republic 3rd. Medical Faculty, Charles University in Prague INTRODUCTION Animals: Adult male Wistar rats, 250-300g, 8-12 rats per group Substances: Drug Full name Psilocin 4-hydroxy dimethyltryptamine LSD fumarate D-lysegid acid diethylamide Mescaline hydrochloride3,4,5-trimethoxy phenethylamine DOB 4-Bromo-2,5-dimethoxy-amphetamine The representatives of main classes of serotonergic hallucinogens - tryptamines (Psilocin, LSD) and phenylethyamines (mescaline, DOB) were used as pharmacological models of psychosis in rats. Regarding the fact, that psychotic state is characterized by impaired processing of information (1), we measured behavioral parameter prepulse inhibition (PPI) of startle reaction in order to asses these changes in rats. However, the main interest of the study was to explore the eletrophysiological mechanisms underlying the behavioral changes using quantitative EEG. METHODS Dose + administration 0.25, 1, 4 mg/kg s.c. 5, 50, 200 μg/kg s.c. 10, 20, 100 mg/kg s.c. 1, 5 mg/kg i.p. Substances were dissolved in saline (or acidified saline in case of psilocin) and applied in a volume of 2ml/kg of animal weight. Saline was administrated to controls. PPI ASR: Sensimotor gating was assessed in the test of prepulse inhibition of acoustic startle reaction (PPI ASR) (SR-LAB San Diego Instruments, USA) 15 minutes after drug administration. The scheme of PPI experiment: 5 minutes of acclimatization with background noise was followed by 15 minutes of PPI registration, where initially 5 isolated pulse alone trials were presented, subsequently followed a pseudo-random sequence of pulse alone, prepulse, prepulse-pulse and no stimulus trials (5 presentation of each). The intensity of stimuli is included in Figure 1. RESULTS - PPI Prepulse inhibition of ASR (Figure 6) LSD and psilocin tended to evoke deficit in PPI ASR, but the only significant effect was observed after the intermediate doses. Mescaline evoked PPI deficit in all doses used. The PPI disruption after DOB did not reach significance level. [email protected] Surgery: The rats were stereotactically implanted under isoflurane anesthesia with 14 electrodes (12 active) on the surface of the frontal, parietal and temporal cortex. Locations of the electrodes (Figure 2) were established based on the stereotactic atlas (2), and electrodes were fixed to the rat’s skull with dental cement. Connectors enabling linkage to the registration system were joined to the electrodes under short-lasting isoflurane anesthesia one day before registration (Figure 3,4). EEG registration: The EEG was recorded using a 21 channel BrainScope amplifier system 7 days after the implantation of the electrodes. Initially, a baseline recording of 10 minutes was obtained, and subsequently the substances were administrated and registration continued for another 40 minutes. Along with the EEG registration, we manually co-registered behavioral activity and inactivity using the Activities program (Figure 5). EEG analysis: The data was digitally filtered (0.5 – 40 Hz) and pre-processed in WaveFinder v.2.3 (separation of EEG signal to parts corresponding to behavioral activity and inactivity). Only signals corresponding to inactivity were used in the further analysis. The length of the selected data for analysis was approximately 1-3 minutes from each part of the signal (baseline and 20-30 minutes after administration). Data were transformed by Fast Fourier Transformation (FFT) and spectral and coherence analyses were performed in Neuroguide Deluxe software v.2.6. 60,00 50,00 40,00 % PPI 30,00 * * * * * 20,00 Figure 5. The scheme of EEG experiment Figure 1 (top). The intensity of PPI stimuli. 10,00 0,00 psilocin (mg/kg) 0 -10,00 0.25 1 LSD (μg/kg) 4 0 5 50 mescaline (mg/kg) 200 0 10 20 100 DOB (mg/kg) 0 1 5 Figure 3,4 (top). Fixation of electrodes, connector Figure 2 (right). Location of electrodes on the rat skull. Figure 6. The diagram of PPI ASR. * = p < 0.05 Statistics: For behavioral experiments a one-way ANOVA with Bonferroni correction was performed. The impact of substances on EEG signal was evaluated using a pair T-test. The significance level was established as p < 0.05. Each animal served as a control (10 minutes of baseline record versus 20-30 minutes after substance administration). RESULTS - QEEG 20 beta high beta gamma ** *** *** *** *** *** -10 -20 -30 -50 0 gamma *** *** *** *** *** *** -20 -30 Figure 7 (left). The diagram of EEG spetra after psilocin, LSD, mescaline and DOB. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 *** ** alpha beta high beta gamma ** ** * -20 -30 0 *** theta alpha beta high beta gamma ** *** *** *** -10 -20 EEG coherences (Figure 8) The inter- and intra-hemispherical coherences were prominently decreased with the maximum in delta (all substances) and theta band (psilocin and LSD). The decrement of intrer-hemispherical coherences was observed in all frequency bands. -30 Figure 8 (down). The diagram of EEG coherences after psilocin, LSD, mescaline and DOB. -40 LSD 200 μg/kg -50 DOB 5 mg/kg 1 Hz 2 Hz 3 Hz 4 Hz 5 Hz 6 Hz 7 Hz 8 Hz 9 Hz 10 Hz 11 Hz 12 Hz 13 Hz 14 Hz 15 Hz 16 Hz 17 Hz 18 Hz 19 Hz 20 Hz 21 Hz 22 Hz 23 Hz 24 Hz 25 Hz 26 Hz 27 Hz 28 Hz 29 Hz 30 Hz 31 Hz 32 Hz 33 Hz 34 Hz 35 Hz 36 Hz 37 Hz 38 Hz 39 Hz 40 Hz -40 10 delta PSILOCIN 4 mg/kg % of change high beta 1 Hz 2 Hz 3 Hz 4 Hz 5 Hz 6 Hz 7 Hz 8 Hz 9 Hz 10 Hz 11 Hz 12 Hz 13 Hz 14 Hz 15 Hz 16 Hz 17 Hz 18 Hz 19 Hz 20 Hz 21 Hz 22 Hz 23 Hz 24 Hz 25 Hz 26 Hz 27 Hz 28 Hz 29 Hz 30 Hz 31 Hz 32 Hz 33 Hz 34 Hz 35 Hz 36 Hz 37 Hz 38 Hz 39 Hz 40 Hz theta % of change delta -10 -50 beta 20 DOB 5 mg/kg 0 alpha -10 -50 20 10 theta -40 1 Hz 2 Hz 3 Hz 4 Hz 5 Hz 6 Hz 7 Hz 8 Hz 9 Hz 10 Hz 11 Hz 12 Hz 13 Hz 14 Hz 15 Hz 16 Hz 17 Hz 18 Hz 19 Hz 20 Hz 21 Hz 22 Hz 23 Hz 24 Hz 25 Hz 26 Hz 27 Hz 28 Hz 29 Hz 30 Hz 31 Hz 32 Hz 33 Hz 34 Hz 35 Hz 36 Hz 37 Hz 38 Hz 39 Hz 40 Hz -40 10 delta 1 Hz 2 Hz 3 Hz 4 Hz 5 Hz 6 Hz 7 Hz 8 Hz 9 Hz 10 Hz 11 Hz 12 Hz 13 Hz 14 Hz 15 Hz 16 Hz 17 Hz 18 Hz 19 Hz 20 Hz 21 Hz 22 Hz 23 Hz 24 Hz 25 Hz 26 Hz 27 Hz 28 Hz 29 Hz 30 Hz 31 Hz 32 Hz 33 Hz 34 Hz 35 Hz 36 Hz 37 Hz 38 Hz 39 Hz 40 Hz alpha % of change % of change 0 theta LSD 200 μg/kg 10 delta MESCALINE 100 MESCALINE 100 mg/kg PSILOCIN 4 mg/kg 20 EEG spectral power (Figure 7) The EEG power spectral analysis revealed general decrease in absolute EEG power in all frequency bands in all drug conditions. After mescaline, the decrease was less pronounced and was mainly in the delta band (for both mescaline and DOB), while the effects of the psilocin and LSD were more widespread within the spectrum. CONCLUSION Serotonergic drugs produced profound electrophysiological changes in rat brain characterized generally by local desynchronization and disconnection of long projections. The decrement of functional connectivity is common finding in patients suffering from schizophrenia (3), indicating the validity of serotonergic models of psychosis. Described EEG changes could be an underlying factor of observed impairment of information processing (disrupted PPI). The experiments also revealed slightly different EEG and PPI pattern of indolamine and phenylethylamine hallucinogens, which can be related to the lack of affinity of phenylethylamines to 5HT1A receptors (4,5). REFERENCES 1. Swerdlow NR et al., 1992. The neural substrates of sensorimotor gating of the startle reflex: a review of recent findings and their implications. Psychopharmacology 6, 176-190. 2. Paxinos G and Watson Ch, 1998. The rat brain in stereotactic coordi- nates, 4th ed. 3. Friston KJ and Firth CD, 1995. Schizophrenia: a disconnection syn drome? Clin. Neurosci. 3, 89-97. 4. Nichols DE, 2004. Hallucinogens. Pharmacol Ther 101(2): 131-81. 5. Halberstadt AL and Geyer M, 2011. Multiple receptor contributes to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61(3):364-81. This poster is financially supported by grants VG20122015080, VG20122015075, NT/13897, MH CZ - DRO (PCP, 00023752), ECGA 278006 and PRVOUK P34.